Skip to main content

and
  1. Article

    Open Access

    Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study

    Drug retention is particularly relevant to assess long-term treatments. This real-world study mainly aimed to describe 1-year retention rate (RR) of subcutaneously administered tocilizumab (TCZ-SC) in patients...

    Pascal Hilliquin, Thomas Barnetche, Athan Baillet in Rheumatology and Therapy (2021)

  2. Article

    Open Access

    Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study

    The main objective of this work was to assess the maintenance of effectiveness of subcutaneous tocilizumab 6 months after switching from intravenous to subcutaneous formulation in patients with rheumatoid arth...

    Jean Darloy, Nicolas Segaud, Jean-Hugues Salmon in Rheumatology and Therapy (2019)